Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Navio MD vs REMEVi

Navio MD
Graded #112

Lower grade

vs+3.700000000000003
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 69.8/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
57
57
Dose & formulationREMEVi +6
77
83
Clinical oversightNavio MD +1
87
86
Labs & monitoringREMEVi +1
54
55
FulfillmentREMEVi +12
85
97
Contract termsREMEVi +14
55
69
Navio MD · left barREMEVi · right bar

The numbers

MetricNavio MDREMEVi
WeighScore69.8/10073.5/100
GradeCC
Scorecard rank#112#70
Semaglutide$345/mo (starting dose, brand-name)$219/mo
Tirzepatide$189/mo (starting dose, compounded)$319/mo
Coverage48 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Navio MD

Graded #112 · C

Strengths

  • LegitScript verified with board-certified providers and US-licensed pharmacies
  • Both compounded and brand-name options
  • 48-state coverage
  • Hours 9am–10pm EST Mon–Sun
  • Transparent tiered pricing: you only pay for your current dose

Where it loses points

  • Not available in Alabama and Mississippi
  • Compounded option is tirzepatide only — no compounded semaglutide listed
  • Also offers women's HRT (broader platform)
  • Pricing is tiered by dose ('as low as'); the entry prices climb as your dose increases
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard